LISTA DE LUCRĂRI REPREZENTATIVE

1. Buicu AL, Cernea S, Benedek I, Buicu CF, Benedek T. Systemic Inflammation and COVID-19 Mortality in Patients with Major Noncommunicable Diseases: Chronic Coronary Syndromes, Diabetes and Obesity. J Clin Med 2021; 10: 1545. doi: 10.3390/jcm10081545, FI (2020): 4,241; autor corespondent.

2. Cernea S, Raz I. NAFLD in type 2 diabetes mellitus - still many challenging questions. Diabetes Metab Res Rev 2021; 37: e3386. doi: 10.1002/dmrr.3386, FI: 4,876.

3. Cernea S, Dima L, Correll CU, Manu P. Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics. Drugs 2020; 80:1763-1781. doi: 10.1007/s40265-020-01393-x, FI: 9,546.

4. Cernea S, Both E, Fodor A. The association of anthropometric parameters with markers of insulin and leptin secretion and resistance in type 2 diabetes mellitus. Rev Rom Med Lab 2020; 28: 299-314. doi: 10.2478/rrlm-2020-0028, FI: 1,027.

5. Rus VA, Chitu M, Cernea S, Benedek I, Hodas R, Zavate R, Nyulas T, Hintea M, Benedek T. Altered nutritional status, inflammation and systemic vulnerability in patients with acute myocardial infarction undergoing percutaneous coronary revascularisation: A prospective study in a level 3 cardiac critical care unit. Nutr Diet 2020; 77: 212–222. doi: 10.1111/1747-0080.12536, FI: 2,333.

6. Cernea S, Raz I. Insulin Therapy: Future Perspectives. Am J Ther 2020; 27: e121-e132. doi: 10.1097/MJT.0000000000001076, FI: 2,688.

7. Cernea S, Both E, Huţanu A, Şular FL, Roiban AL. Correlations of serum leptin and leptin resistance with depression and anxiety in patients with type 2 diabetes. Psychiatry Clin Neurosci 2019; 73: 745–753. doi: 10.1111/pcn.12922, FI: 3,351.

8. Cernea S, Roiban AL, Both E, Huţanu A. Serum leptin and leptin resistance correlations with NAFLD in patients with type 2 diabetes. Diabetes Metab Res Rev 2018; 34: e3050. doi: 10.1002/dmrr.3050, FI: 4,758.

9. Cernea S, Cahn A, Raz I. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. Expert Rev Clin Pharmacol 2017; 10: 535-547. doi: 10.1080/17512433.2017.1300059, FI: 2,758.

10. Cernea S, Şular FL, Huţanu A, Voidăzan S. Markers of cognitive impairment in patients with type 2 diabetes. Rev Rom Med Lab 2016; 24: 161-176. 10.1515/rrlm-2016-0023, FI: 0,325.